Drugs / Autologous Treg-depleted lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00986518 | Oct 2012 → Feb 2013 | colorectal cancer | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Treg-depleted lymphocytes | “Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.” NCT00986518 ↗ |
| Action | Deplete | “by selectively depleting regulatory T-cell during a controlled amount of time” NCT00986518 ↗ |
| Modality | Cell therapy | “an autologous cell therapy aiming at mounting an efficient immune anti-tumor response” NCT00986518 ↗ |